Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A 78-Year-Old Man With Shortness of Breath After Radioembolization of the Liver.
Chest
October 2024
Department of Medicine, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia. Electronic address:
Article Synopsis
- * His GIST was initially diagnosed 10 years prior, leading to surgery, but recent biopsies confirmed liver metastases.
- * He had pre-existing heart conditions but no lung issues before the radioembolization treatment with Y-90 microspheres, which he underwent after starting imatinib therapy.
Arterial hypoperfusion as a negative predictive marker for primary hepatic malignancies treated with Y-90 glass microsphere transarterial radioembolization.
Front Oncol
August 2024
School of Medicine, Washington University in St. Louis, St. Louis, MO, United States.
Background: Radioembolization with yttrium-90 (Y-90) is utilized to treat primary liver malignancies. The efficacy of this intra-arterial therapy in arterially hypoperfused tumors is not known.
Methods: We reviewed data of patients with primary liver tumors treated with Y-90 prescription doses of at least 150 Gy.
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.
Blood Adv
September 2024
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission with first-line therapy, as well as in chemotherapy-sensitive relapse if allogeneic transplant is not an option. CD25 is a targetable protein often highly expressed in PTCLs.
View Article and Find Full Text PDFEfficacy of Selective Internal Radiation Therapy for Hepatocellular Carcinoma Post-Incomplete Response to Chemoembolization.
Pharmaceuticals (Basel)
December 2023
Department of Nuclear Medicine, CHU Bordeaux, 33000 Bordeaux, France.
Article Synopsis
- - Hepatocellular carcinoma (HCC) is a major global health issue, being one of the most common cancers and a leading cause of cancer deaths, with intra-arterial therapies like TACE and SIRT being key treatment options for non-resectable cases.
- - TACE is typically used for patients with stage B HCC, while SIRT has shown promising results in patients previously treated with TACE, despite not having an official role in treatment guidelines.
- - A study involving 23 patients indicated that SIRT post-TACE resulted in a 73.8% objective response rate, with 56.5% achieving complete response, highlighting SIRT's potential effectiveness despite the complications associated with TACE.
Yttrium-90 Transarterial Radioembolization of Primary Lung Cancer Metastases to the Liver.
J Vasc Interv Radiol
February 2024
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: To assess whether yttrium-90 transarterial radioembolization (TARE) is safe and effective in the treatment of primary lung cancer metastases to the liver (LCML).
Methods And Methods: This retrospective study included 57 patients with LCML who were treated with 79 TARE treatments. Histology included non-small cell lung cancer (NSCLC) (n = 27), small cell lung cancer (SCLC) (n = 17), and lung carcinoid (LC) (n = 13).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!